Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Merrill Cuts NPS Pharma Rating


Merrill Lynch cut NPS Pharmaceuticals (NPSP) to near-term buy from strong buy but kept its long-term strong buy rating.

Analyst Eric Ende says that while he is convinced that NPS's Preos is a promising drug for severe osteoporosis, the timing of its launch is increasingly uncertain. According a 10Q filing by NPS, it has only enough supply of Preos to meet clinical trial requirements into Q3 of 2002. The supply issue is due to a recent problem at its contract fill & finish manufacturer, which resulted in material that did not meet its release specifications. Ende says this could limit Preos' clinical trial supply; hence, Phase III trials may have to reduce the number of patients, or possibly delay the Preos launch by 2-1/2 years.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus